Gene Therapy 'Luxturna' Restores Lost Vision, Wins Top Scientific Honor
Married couple Jean Bennett and Albert Maguire developed treatment that helped patient see child's face for first time
By 
🔗 Original sourceOn January 23, 2018, a 45-year-old woman with a rare genetic disorder gained the ability to see her child's face for the first time, thanks to a revolutionary gene therapy called Luxturna. This groundbreaking treatment, developed by married couple Jean Bennett and Albert Maguire, has now been recognized with the Breakthrough Prize in Life Sciences, often referred to as the 'Oscar of science'.
The Science Behind Luxturna
According to an account by the Los Angeles Times, Jean Bennett and Albert Maguire, a married couple and ophthalmologists, collaborated on the development of Luxturna, a gene therapy designed to treat Leber congenital amaurosis (LCA), a rare genetic disorder that causes severe vision loss or blindness from birth. The treatment involves injecting a functional copy of the RPE65 gene into the retina, where it enables cells to produce a protein crucial for vision. In clinical trials, Luxturna was shown to significantly improve visual acuity in patients with LCA. One patient, a 45-year-old woman, was able to see her child's face for the first time after receiving the treatment. According to Bennett, 'The improvement in vision was not just statistically significant, it was clinically significant, and it was meaningful to the patients.'
Implications for Genetic Disorders
The success of Luxturna has significant implications for the treatment of genetic disorders. As Dr. Maria Millan, president and CEO of the California Institute for Regenerative Medicine, noted, 'Gene therapy has the potential to transform the lives of patients with genetic diseases.' Luxturna is one of the first gene therapies to be approved by the FDA for a genetic disorder, paving the way for further research and development of similar treatments. For patients and families affected by genetic disorders, Luxturna offers new hope for restoring lost function and improving quality of life.
“According to Bennett, 'We've been working on this for 25 years, and it's been a long and winding road. But to see patients gaining vision, it's just the most wonderful thing.'”
Uncertainty and Future Directions
Despite the success of Luxturna, there are still many questions to be answered. One of the biggest challenges facing researchers is the long-term efficacy and safety of gene therapy. As Dr. Maguire noted, 'We're still learning about the durability of the treatment and potential side effects.' Additionally, the high cost of Luxturna, which is priced at $1 million per patient, raises concerns about accessibility and affordability. Further research is needed to address these challenges and ensure that gene therapy is available to those who need it most.
Key Takeaways
- Luxturna is a gene therapy developed by Jean Bennett and Albert Maguire to treat Leber congenital amaurosis (LCA).
- The treatment involves injecting a functional copy of the RPE65 gene into the retina.
- Luxturna has been recognized with the Breakthrough Prize in Life Sciences.
- The treatment has been shown to significantly improve visual acuity in patients with LCA.
- The high cost of Luxturna raises concerns about accessibility and affordability.
What's Next
In the next 24-72 hours, researchers and clinicians will be monitoring patients who have received Luxturna to assess the treatment's long-term effects. Bennett and Maguire will likely continue to work on refining the treatment and exploring its applications for other genetic disorders. As the scientific community continues to advance the field of gene therapy, we can expect to see new breakthroughs and innovations in the years to come.
Interestingly, the human eye has the highest concentration of genes of any organ in the body, with over 100 genes contributing to its development and function.
The story of Luxturna serves as a testament to the power of scientific innovation and collaboration. For patients and families affected by genetic disorders, this breakthrough offers new hope for restoring lost function and improving quality of life. As researchers continue to advance the field of gene therapy, we can expect to see new breakthroughs and innovations in the years to come.
